Avecho Biotechnology Ltd
Avecho Biotechnology Advances Phase III Insomnia Trial to Full Enrolment Size
Avecho Biotechnology Phase III insomnia trial moves to full enrolment after DMB recommendation; no serious adverse events in first 244 participants.
Avecho Biotechnology Receives US and EU Patent Allowances for Proprietary CBD Soft-Gel Capsule
Avecho Biotechnology (ASX: AVE) has received patent allowances from both the US Patent and Trademark Office and the European Patent Office for its cannabidiol (CBD) TPM soft-gel capsule.
Avecho Biotechnology advances CBD insomnia trial with Sandoz licensing deal and funding
Avecho Biotechnology (ASX: AVE) has received a maiden payment of approximately $4.7 million (US$3m) from international generic and biosimilar medicines specialist Sandoz. The payment forms part of a recently signed licensing agreement for the commercial rights to develop Avecho’s proprietary cannabidiol (CBD) product for insomnia treatment in Australia. Avecho has granted Sandoz exclusive commercial rights […]
Avecho Biotechnology signs exclusive licensing deal with Sandoz for CBD insomnia treatment
Avecho Biotechnology (ASX: AVE) has signed an exclusive 10-year development and licensing agreement with Swiss generic pharmaceuticals developer Sandoz Group to investigate the commercialisation of a cannabidiol (CBD) capsule for insomnia in Australia. The companies have identified a market in which nearly 9.5 million Australians experience symptoms of insomnia, with approximately 3.6 million of those […]